Skip to Main Content

Peter A. Ljubenkov


Natural science enthusiast, amateur artist and proud dad

Dr. Peter A. Ljubenkov is a behavioral neurologist who specializes in caring for patients experiencing memory, language and behavioral changes due to neurological conditions, such as Alzheimer's disease, Lewy body dementia and other causes of dementia. He has special expertise in diagnosing and treating frontotemporal dementia (a group of neurodegenerative diseases that affect the frontal and temporal lobes) and related conditions, including progressive supranuclear palsy and corticobasal degeneration. Ljubenkov also serves as the associate fellowship director of the UCSF Memory and Aging Center's Behavioral Neurology Training Program fellowship, which trains doctors for careers in research and clinical care involving patients with dementia.

In research, Ljubenkov is active in clinical therapeutic trials, studies enrolling human participants to explore new potential treatments for patients with dementia.

Ljubenkov earned his medical degree at Lewis Katz School of Medicine at Temple University. He completed a residency in neurology at the University of California, San Diego, followed by a fellowship in behavioral neurology at UCSF.

  • Education

    Lewis Katz School of Medicine, MD, 2011

  • Residencies

    UC San Diego, Neurology, 2015

  • Fellowships

    UCSF, Behavioral Neurology, 2018

  • Academic Title

    Assistant Professor

We are entering a renaissance of discoveries in the treatment of dementia. It is my passion to aid the search for a cure.

Where I see patients (1)

    My reviews


    Overall Experience
    39 Ratings
    Explained things in a way that was easy to understand
    39 Ratings
    Did the doctor pay attention to your concerns
    39 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    37 Ratings
    Knew the important information about your medical history
    39 Ratings
    The provider showed respect for what you had to say
    38 Ratings
    The provider spent enough time with me
    39 Ratings
    Decorative Caduceus

    Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

    Assess adverse events during 6 months administration of Verdiperstat or Placebo


    Decorative Caduceus

    A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

    The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior & Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by ...


    Decorative Caduceus

    Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

    The ADAS-Cog is an in-person examiner-administered, structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing ...